SPH SINE, a subsidiary of China’s Shanghai Pharma, acquired greater China rights for two microbiome therapies from Korea’s KoBioLabs in a $110 million deal. SPH SINE made an upfront payment of $2.5 million, with the rest of the licensing fee payable for milestones. The two candidates are KBL697, which is aimed at psoriasis and IBD, and KBL693, which is aimed at atopic dermatitis and asthma. Both products are preparing for US Phase II trials. KoBioLabs will transfer the technology for the two candidates to SPH SINE, which will be responsible for China trials and commercialization.
For further information, see Chinabio Today (http://www.chinabiotoday.com/articles/shanghai-pharma-microbiome-110-million)